Reverie Labs leverages machine learning, physics-based modeling, and massive-scale computational infrastructure to engineer next-generation small-molecule kinase inhibitors. The company’s technology includes predictive tools, focused molecular generation methods, and a scalable cloud framework to explore chemical space. It is advancing a lead program that is rapidly moving toward the clinic and targets a well-validated disease mechanism with highly specific, brain-penetrant kinase inhibitors. Reverie supplements its internal pipeline through partnerships, including a multi-target strategic collaboration agreement with Roche and Genentech. The company plans to use new proceeds to advance internal and partnered drug discovery programs toward the clinic, further develop its computational discovery platform, and grow its cross-disciplinary team of scientists and engineers. Reverie is led by co-founders Jonah Kallenbach (CEO) and Ankit Gupta (CTO) and is based in Cambridge, Mass.

Total raised

$25M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2021